ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Abbott Laboratories and Celera Genomics have formed a cancer drug collaboration. The venture will develop antibodies and small molecules against overexpressed cell-surface proteins that Celera has validated as therapeutic targets using proteomics research. Abbott will screen and further research the proteins, and Celera will receive payments from Abbott if certain milestones are reached. The two firms may elect to jointly fund development and commercialization of resulting drug candidates. If either firm elects not to develop a product, the deal will revert to a milestone-and-royalty structure.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter